The federal government said Sept. 23 that it will cover the cost for 60,000 doses of bebtelovimab, Eli Lilly’s COVID-19 antibody drug. The news comes about a month after the drugmaker started selling the treatment commercially for $2,000 per dose.
Read the full post on Becker's Hospital Review - Healthcare News
